Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Authors
Casadio, M.Cardinale, V.
Klümpen, H. J.
Morement, H.
Lacasta, A.
Koerkamp, B. G.
Banales, J.
Alvaro, D.
Valle, Juan W
Lamarca, Angela
Affiliation
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; Department of Gastroenterology, Sapienza University of Rome, Rome, Italy. Medical-Surgical and Biotechnologies Sciences, Polo Pontino, Sapienza University of Rome, Latina, Italy. Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. AMMF-The Cholangiocarcinoma Charity, Stansted, UK. Medical Oncology Department, Hospital Universitario Donostia, San Sebastian, Spain; Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute-Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain. Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute-Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain. Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK. Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK. Electronic address: angela.lamarca@nhs.net.Issue Date
2022
Metadata
Show full item recordAbstract
Background Cholangiocarcinomas (CCAs) are a rare group of malignancies characterized by dismal prognosis. There are currently no standardized guidelines for multidisciplinary teams (MDTs) in CCAs. Material and methods An online survey was built with the aim of defining the current practice of MDTs in CCAs and identifying possible areas of improvement, providing minimum standards of practice for an ideal CCA MDT. Analysis of the replies regarding current and ideal MDT practice was carried out by calculating weighted average (WA) of likelihood of every item. The survey was shared with members of the European Network for the Study of Cholangiocarcinoma and other medical centers with expertise in biliary tract cancer part of the EURO-CHOLANGIO-NET (European Cholangiocarcinoma Network: https://eurocholangionet.eu/) COST Action CA18122 initiative. Results The role of the MDT coordinator was a recognized priority in an ideal well-functioning MDT (WA 3.31/4), together with providing minimum clinical information before the meeting to secure adequate case preparation (WA 3.54/4). Optimal frequency of MDT meetings was weekly according to 76.92% of the participants; 73.06% believed that ideally all newly diagnosed patients and each new treatment should be discussed, although that happened only in less than half of the MDTs (46.15%) in current practice. Most participants stated that they always (46.15%) or often (50.00%) used guidelines, mainly international (61.00%) (European and American), followed by national/local (39.00%). We defined the ideal setup of a CCA MDT, identifying specialists whose presence is mandatory with WA >3.0 (oncologist, clinician responsible for patient’s care, surgeon, diagnostic and interventional radiologist, hepatologist, pathologist, endoscopist and gastroenterologist) and those whose presence would be recommended with a WA <3.0 (palliative care, nurse, dietitian, basic researcher, psychologist and social worker). Conclusions Our identified minimum requirements should be taken into account at the time of CCA MDT setup and quality assessment.Citation
Casadio M, Cardinale V, Klümpen H-J, Morement H, Lacasta A, Koerkamp BG, et al. Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Vol. 7, ESMO Open. Elsevier BV; 2022. p. 100377.Journal
ESMO OpenDOI
10.1016/j.esmoop.2021.100377PubMed ID
35093741Additional Links
https://dx.doi.org/10.1016/j.esmoop.2021.100377Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.esmoop.2021.100377